| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA071167 |
| P698 | PubMed publication ID | 17928597 |
| P50 | author | Eric Winer | Q16887072 |
| Larry Norton | Q37644083 | ||
| Gloria Broadwater | Q87013225 | ||
| James N Ingle | Q89668737 | ||
| Donald L. Weaver | Q110141382 | ||
| Silvana Martino | Q114412398 | ||
| P2093 | author name string | Donald A. Berry | |
| Susan Edgerton | |||
| David Cowan | |||
| Daniel F. Hayes | |||
| Matthew J. Ellis | |||
| Clifford A. Hudis | |||
| Lynn G. Dressler | |||
| Lori J. Goldstein | |||
| Ann D. Thor | |||
| I. Craig Henderson | |||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| paclitaxel | Q423762 | ||
| P304 | page(s) | 1496-1506 | |
| P577 | publication date | 2007-10-11 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | |
| P478 | volume | 357 |
| Q37109643 | "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. |
| Q84735254 | 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response |
| Q48320735 | 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology |
| Q36432567 | A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer |
| Q58730370 | A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown Mutation Status |
| Q39751877 | A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. |
| Q45782977 | A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer |
| Q60914625 | A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients |
| Q46207177 | A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer |
| Q38181995 | Accounting for linkage disequilibrium in association analysis of diverse populations |
| Q26853619 | Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline |
| Q37099589 | Adjuvant chemotherapy for luminal A breast cancer: a prospective study comparing two popular chemotherapy regimens |
| Q46848022 | Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. |
| Q36733078 | Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial |
| Q37376169 | Adjuvant targeted therapy in early breast cancer. |
| Q33560459 | Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). |
| Q38046581 | Adjuvant treatments for triple-negative breast cancers |
| Q33990934 | Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer |
| Q96304064 | An Algorithm for Generating Individualized Treatment Decision Trees and Random Forests |
| Q35064705 | An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients |
| Q52645773 | An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients. |
| Q50040088 | An update on first line therapies for metastatic breast cancer |
| Q53318118 | Analysis of cancer marker in tissues with Hadamard transform fluorescence spectral microscopic imaging. |
| Q34651968 | Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity |
| Q34348403 | Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models |
| Q36950483 | Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial |
| Q41729795 | Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines |
| Q36419109 | Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer |
| Q36051500 | Association of HER-2 copy number and HER-2/CEP-17 ratio with neoadjuvant taxane-containing chemotherapy sensitivity in locally advanced breast cancer |
| Q39870740 | Automated quantitative assessment of HER-2/neu immunohistochemical expression in breast cancer |
| Q37605747 | BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different |
| Q35931900 | Basal breast cancer: a complex and deadly molecular subtype |
| Q99570496 | Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment |
| Q37298667 | Biologically conformal treatment: biomarkers and functional imaging in radiation oncology |
| Q34058510 | Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer |
| Q42791324 | Biomarker Research in Breast Cancer |
| Q36295142 | Biomarkers in Breast Cancer - An Update |
| Q37155629 | Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. |
| Q37249243 | Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival |
| Q40650720 | Breast cancer survival in African-American women by hormone receptor subtypes. |
| Q35584364 | Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score |
| Q33763357 | Calculator for ovarian carcinoma subtype prediction |
| Q37349840 | Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy? |
| Q26743510 | Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes |
| Q37356034 | Cancer biomarker HER-2/neu in breast cancer in Indian women |
| Q54506148 | Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. |
| Q38081243 | Chemotherapy regimens in early breast cancer: major controversies and future outlook |
| Q46397645 | Choosing a taxane for adjuvant treatment of breast cancer: more than a flip of the coin? |
| Q54509553 | Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? |
| Q34315684 | Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. |
| Q37332490 | Clinical implications of using molecular diagnostics for ovarian cancers |
| Q37602286 | Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept |
| Q33775506 | Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology |
| Q35555963 | Clinical trials in the era of personalized oncology |
| Q36726996 | Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network |
| Q42474341 | Clinicopathological features and treatment strategy for triple-negative breast cancer |
| Q46293922 | Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer |
| Q37641078 | Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer |
| Q37947898 | Commentary on adjuvant chemotherapy for the older woman with early stage breast cancer |
| Q30315367 | Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial |
| Q37750063 | Current controversies in the management of breast cancer |
| Q33561953 | Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer |
| Q34234936 | DNA repair and personalized breast cancer therapy |
| Q37247163 | DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. |
| Q36671882 | Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer |
| Q28728830 | Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel |
| Q37822734 | Do anthracyclines still have a role in adjuvant chemotherapy of breast cancer? |
| Q42344024 | Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer? |
| Q37177949 | Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer |
| Q38475122 | Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3'-deoxy-3'-[¹⁸F]fluorothymidine in preclinical tumor models. |
| Q37165930 | Effect of chemotherapy for luminal a breast cancer. |
| Q54453782 | Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. |
| Q36423995 | Efficacy and feasibility of neoadjuvant chemotherapy with FEC 100 followed by weekly paclitaxel for operable breast cancer |
| Q37997046 | Efficacy and pharmacogenomic biomarkers in breast cancer |
| Q39683758 | Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. |
| Q28372484 | Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer |
| Q37903140 | Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials |
| Q35145663 | Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey |
| Q38808336 | Estrogen receptor alpha (ESR1)-signaling regulates the expression of the taxane-response biomarker PRP4K. |
| Q39475671 | Estrogen receptor-α directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer |
| Q46624267 | European oncologists' preferences for the management of breast cancer: case presentations and expert commentary |
| Q38089837 | Evaluation of HER2 in breast cancer: reality and expectations. |
| Q37010568 | Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. |
| Q34640536 | Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Co |
| Q35663809 | Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study |
| Q37298361 | Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer |
| Q36102798 | Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial |
| Q84903929 | Facilitating consensus by examining patterns of treatment effects |
| Q34187204 | First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis |
| Q37802908 | From genomic landscapes to personalized cancer management—is there a roadmap? |
| Q34274152 | GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy |
| Q39500345 | Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. |
| Q34193932 | Genomic index of sensitivity to endocrine therapy for breast cancer. |
| Q35744973 | HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. |
| Q36319233 | HER2 over-expression and response to different chemotherapy regimens in breast cancer |
| Q35065084 | High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. |
| Q82317830 | How do I treat "triple-negative" disease |
| Q81356084 | How not to treat cancer |
| Q36551617 | Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? |
| Q35807180 | Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. |
| Q33739253 | Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study |
| Q38298124 | Incorporation of biomarkers in phase II studies of recurrent glioblastoma |
| Q41234329 | Influence of delayed initiation of adjuvant chemotherapy on breast cancer survival is subtype-dependent |
| Q37159488 | Ixabepilone: a new microtubule-targeting agent for breast cancer |
| Q33572318 | LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer |
| Q24648828 | Latent bone metastasis in breast cancer tied to Src-dependent survival signals |
| Q34095952 | Limitations in Adjuvant Breast Cancer Therapy: The Predictive Potential of Pharmacogenetics and Pharmacogenomics. |
| Q42667963 | Liquid Biopsy Prevents Inaccurate Her2 Status Determination by in situ Hybridization in a Patient with Invasive Ductal Adenocarcinoma of the Breast: Case Report |
| Q35580011 | Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy |
| Q37650748 | Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen. |
| Q37894617 | Mammalian plasma membrane proteins as potential biomarkers and drug targets |
| Q37625436 | Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. |
| Q30430971 | Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma |
| Q83602951 | Meta-analysis of concomitant compared to sequential adjuvant trastuzumab in breast cancer: the sooner the better |
| Q21195215 | MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer |
| Q37146751 | Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance |
| Q34375087 | Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance |
| Q37633179 | Molecular imaging of breast cancer. |
| Q38444869 | Molecular imaging using PET for breast cancer |
| Q41128277 | Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models |
| Q33692020 | Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue |
| Q53789447 | Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy. |
| Q36117650 | Moving from correlative science to predictive oncology |
| Q33745113 | Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome |
| Q37347130 | Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. |
| Q33561166 | Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897 |
| Q37513837 | Neoadjuvant chemotherapy for "triple negative" breast cancer: a review of current practice and future outlook |
| Q37817838 | Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept |
| Q34253719 | Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool |
| Q54481763 | Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers. |
| Q41517836 | Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival |
| Q36117711 | Non-invasive proteomics-thinking about personalized breast cancer screening and treatment |
| Q37347521 | Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient |
| Q38235713 | Optimal adjuvant chemotherapy in breast cancer: selection of agents |
| Q33698446 | Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment |
| Q39661010 | Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts |
| Q50933865 | Orally administered S-1 suppresses circulating endothelial cell counts in metastatic breast cancer patients. |
| Q35100315 | Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations |
| Q33883406 | PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). |
| Q36718459 | PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer |
| Q39938932 | PIK3CA mutations and BRCA1 expression in breast cancer: potential biomarkers for chemoresistance |
| Q36181642 | PRP4K is a HER2-regulated modifier of taxane sensitivity |
| Q36212421 | Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. |
| Q90645887 | Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel |
| Q36825817 | Pathological complete response rate in hormone receptor-negative breast cancer treated with neoadjuvant FEC, followed by weekly paclitaxel administration: A retrospective study and review of the literature |
| Q51828510 | Personalized medicine in oncology: the future is now. |
| Q37565645 | Pharmacotherapy of triple-negative breast cancer |
| Q37691181 | Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. |
| Q38454847 | Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancer |
| Q35775850 | Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation |
| Q35949291 | Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions |
| Q57904482 | Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial |
| Q55080728 | Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer. |
| Q36133814 | Predictive Factors and Value of ypN+ after Neoadjuvant Chemotherapy in Clinically Lymph Node-Negative Breast Cancer |
| Q38047337 | Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. |
| Q55066764 | Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. |
| Q86933946 | Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy |
| Q34059719 | Predictors of recurrence in breast cancer patients with a pathologic complete response after neoadjuvant chemotherapy. |
| Q37341013 | Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients |
| Q34081146 | Preservation of fertility in patients with cancer |
| Q42726594 | Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin |
| Q36026913 | Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype |
| Q42470916 | Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial |
| Q24597456 | Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial |
| Q42871099 | Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients |
| Q35889568 | Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial |
| Q37411636 | Qualitative age interactions in breast cancer studies: mind the gap. |
| Q34423520 | Randomized adjuvant trials in oncology: a necessity or time-consuming luxury? |
| Q47107032 | Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer |
| Q46573303 | Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. |
| Q64237541 | Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer |
| Q60300896 | Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer |
| Q34167327 | Recent advances in managing triple-negative breast cancers |
| Q37208730 | Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. |
| Q37208757 | Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. |
| Q46047035 | Receptor-based predictors of response in breast cancer |
| Q21144332 | Retracted: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer |
| Q84723308 | Retrospective subset analyses in early breast cancer revisited |
| Q36738790 | Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? |
| Q92800951 | Robustifying Trial-Derived Optimal Treatment Rules for A Target Population |
| Q46203772 | Role of ErbB2 in selection for adjuvant tamoxifen or aromatase inhibitors |
| Q45967836 | Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India. |
| Q37206289 | Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial |
| Q34719626 | Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. |
| Q61136284 | Stromal PTEN determines mammary epithelial response to radiotherapy |
| Q27691414 | Systemic treatment strategies for triple-negative breast cancer. |
| Q36145430 | TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer |
| Q37208764 | TLE3 as a candidate biomarker of response to taxane therapy |
| Q36027073 | TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial |
| Q34234217 | TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial |
| Q33847811 | Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction |
| Q26824766 | Targeting angiogenesis in gynecologic cancers |
| Q54483843 | Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy. |
| Q38104568 | Taxane benefit in breast cancer--a role for grade and chromosomal stability |
| Q44869105 | Taxanes as primary chemotherapy for early breast cancer: meta-analysis of randomized trials |
| Q37500101 | Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions |
| Q37649479 | Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer |
| Q34424285 | Testing for HER2 in Breast Cancer: A Continuing Evolution |
| Q55096327 | The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 tria |
| Q57580751 | The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer |
| Q37992829 | The adjuvant treatment of HER2-positive breast cancer |
| Q38180001 | The application of Oncotype DX in early-stage lymph-node-positive disease |
| Q34363400 | The epidermal growth factor receptor family in breast cancer |
| Q34102670 | The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer |
| Q81746514 | The remarkable "paclitaxel story": how many chapters remain to be written? |
| Q38018259 | The role of targeted therapy and biomarkers in breast cancer treatment |
| Q26798356 | The role of taxanes in triple-negative breast cancer: literature review |
| Q43249177 | The screening mammography paradox: better when found, perhaps better not to find |
| Q46573306 | The taxane limbo: how low can we go? |
| Q37002727 | Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes |
| Q37842506 | Therapeutic management of breast cancer in the elderly |
| Q24633384 | Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan |
| Q38424397 | Therapies for triple negative breast cancer |
| Q35572763 | Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? |
| Q37301691 | Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. |
| Q46869737 | Translation, please |
| Q37815623 | Treatment of triple negative breast cancer (TNBC): current options and future perspectives |
| Q34331406 | Treatment options for patients with triple-negative breast cancer |
| Q36584831 | Tree-based methods for individualized treatment regimes |
| Q46251579 | Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer. |
| Q34274939 | Triple-negative breast cancer |
| Q37630082 | Triple-negative breast cancer--current status and future directions |
| Q35692146 | Triple-negative breast cancer: adjuvant therapeutic options |
| Q36061177 | Triple-negative breast cancer: are we making headway at least? |
| Q33769821 | Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease |
| Q37809844 | Triple-negative breast cancer: epidemiology and management options |
| Q33900930 | Triple-negative breast cancer: role of specific chemotherapy agents |
| Q37687380 | Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features |
| Q37613250 | Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. |
| Q47988029 | Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer. |
| Q37755092 | Type I receptor tyrosine kinases as predictive or prognostic markers in early breast cancer |
| Q24620957 | Understanding and treating triple-negative breast cancer |
| Q93164318 | Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report |
| Q35007222 | Use of archived specimens in evaluation of prognostic and predictive biomarkers |
| Q37437491 | Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. |
| Q34328227 | Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis |
| Q35688776 | Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study |
| Q37346811 | Weekly paclitaxel in the adjuvant treatment of breast cancer. |
| Q35146274 | p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). |
Search more.